These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37663770)

  • 1. ChIP-chip data for identifying target genes and consensus binding sequences of mutant p53 in MDA-MB-468 breast cancer cells.
    Le MNU; Ning Y; Zhou J
    Data Brief; 2023 Oct; 50():109499. PubMed ID: 37663770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences.
    Brázdová M; Quante T; Tögel L; Walter K; Loscher C; Tichý V; Cincárová L; Deppert W; Tolstonog GV
    Nucleic Acids Res; 2009 Apr; 37(5):1486-500. PubMed ID: 19139068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
    Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
    Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
    Lundine D; Annor GK; Chavez V; Maimos S; Syed Z; Jiang S; Ellison V; Bargonetti J
    Mol Cancer Res; 2022 Dec; 20(12):1799-1810. PubMed ID: 36074101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters.
    Dell'Orso S; Fontemaggi G; Stambolsky P; Goeman F; Voellenkle C; Levrero M; Strano S; Rotter V; Oren M; Blandino G
    OMICS; 2011 May; 15(5):305-12. PubMed ID: 21332394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance.
    Sankala H; Vaughan C; Wang J; Deb S; Graves PR
    Arch Biochem Biophys; 2011 Aug; 512(1):52-60. PubMed ID: 21621504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of p53 in regulation of hematopoiesis in health and disease.
    Barajas S; Cai W; Liu Y
    Curr Opin Hematol; 2022 Jul; 29(4):194-200. PubMed ID: 35787548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hidden Markov model for analyzing ChIP-chip experiments on genome tiling arrays and its application to p53 binding sequences.
    Li W; Meyer CA; Liu XS
    Bioinformatics; 2005 Jun; 21 Suppl 1():i274-82. PubMed ID: 15961467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.
    Ellison V; Annor GK; Freedman C; Xiao G; Lundine D; Freulich E; Prives C; Bargonetti J
    Oncotarget; 2021 Jun; 12(12):1128-1146. PubMed ID: 34136083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
    Shtraizent N; Matsui H; Polotskaia A; Bargonetti J
    Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010022. PubMed ID: 26703669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preferred binding of gain-of-function mutant p53 to bidirectional promoters with coordinated binding of ETS1 and GABPA to multiple binding sites.
    Vaughan CA; Deb SP; Deb S; Windle B
    Oncotarget; 2014 Jan; 5(2):417-27. PubMed ID: 24481480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ChIP-on-chip to identify mutant p53 targets.
    Goeman F; Fontemaggi G; Blandino G
    Methods Mol Biol; 2013; 962():211-26. PubMed ID: 23150450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 induces distinct epigenetic states at its direct target promoters.
    Vrba L; Junk DJ; Novak P; Futscher BW
    BMC Genomics; 2008 Oct; 9():486. PubMed ID: 18922183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
    Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
    Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
    Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.
    Qiu WG; Polotskaia A; Xiao G; Di L; Zhao Y; Hu W; Philip J; Hendrickson RC; Bargonetti J
    NPJ Breast Cancer; 2017; 3():. PubMed ID: 28232952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.
    Annor GK; Elshabassy N; Lundine D; Conde DG; Xiao G; Ellison V; Bargonetti J
    Front Cell Dev Biol; 2021; 9():772315. PubMed ID: 34881245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.